Information for continuing education (CE) credit

**TEG of War: When to Utilize Tranexamic Acid**

Activity date: April 21, 2022

Course director: Kate Lowrey, PharmD

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety.
2. After the course, you will receive an email with instructions that you will need to obtain your CE credit.
3. **Complete the process no later than June 05, 2022.**

Upon successful completion of the course requirements, you will be able to print your CE certificate (with the exception of pharmacists and pharmacy technicians.)

**Important note for pharmacists and pharmacy technicians**

All credit awarded to pharmacists and pharmacy technicians must be via CPE Monitor; paper certificates and e-certificates are not valid for licensure/certification submission. Pharmacists and pharmacy technicians will be able to print individual statements of credit and their transcripts from their NABP e-profile created at [www.mycpemonitor.net](http://www.mycpemonitor.net) or [www.nabp.net](http://www.nabp.net).

1. Please provide an accurate **NABP ID number** and **date of birth** (**mm/dd** – do not include birth year).
2. Vizient will upload your **NABP ID number** and **date of birth** into CPE Monitor within 24 hours after the completion of all steps required to receive credit.

If your **NABP ID number** and/or **date of birth** are returned as invalid after the upload, Vizient will make one attempt to contact you for corrections within a 45-day window. After the 45-day window expires, Vizient will not accept the information, and Vizient will not be able to process your CE credit.

**Learning objectives**

1. Identify laboratory values where tranexamic acid use would be indicated
2. List patient characteristics where tranexamic acid administration provides benefit
3. Critique literature evaluating tranexamic acid in various clinical settings

**Pharmacy technician learning objectives**

1. List at least one indication for tranexamic acid including off label
2. Describe compounding procedure for tranexamic acid



**Joint Accreditation Statement:**

In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation Statement:**

#### PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

Universal Activity Number: JA0006103-0000-22-014-L01-P

Universal Activity Number: JA0006103-0000-22-014-L01-T

**Identification, Mitigation, and Disclosure of Relevant Financial Relationships**

As an accredited provider of continuing education**,** Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

**Ineligible companies** – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

**FDA Off-Label Use**

Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

### DISCLOSURE STATEMENTS:

**Absence of Relevant Financial Relationships**

The following planners, faculty, and others in control of educational content have no relevant financial relationships with ineligible companies.

* “None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

Planning committee:

Michael Perza, PharmD, BCPS

Clinical Pharmacist

ChristianaCare

Kate Lowrey, PharmD

PGY-1 Pharmacy Practice Resident

ChristianaCare

Presenter:

Kate Lowrey, PharmD

PGY-1 Pharmacy Practice Resident

ChristianaCare